Ublituximab. Good results as of last November

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.
Post Reply
User avatar
frodo
Family Elder
Posts: 1330
Joined: Wed Dec 02, 2009 3:00 pm
Contact:

Ublituximab. Good results as of last November

Post by frodo » Tue Mar 12, 2019 5:40 am

Poster presented at the 26th Annual Meeting of the European Charcot Foundation, 15-17 November, 2018, Baveno, Italy

https://eu.eventscloud.com/file_uploads ... ubanks.pdf

Conclusions:

- Annualized Relapse Rate (ARR) of 0.07 was observed at Week 48, with 93% of subjects being relapse free.
- 74% of subjects fulfilled the criteria for NEDA.
- Median B cell depletion was >99% at the primary analysis point of Week 4 (n=48), and maintained at Week 24 and Week 48.
- No T1 Gd-enhancing lesions detected in any subjects at Week 24 or 48 (100% reduction; p=0.003).
- Subjects saw 10.6% reduction in total T2 lesion volume from baseline to Week 48 (p=0.002).
- Ublituximab was well tolerated and the most frequent AEs (all Grade 1 or 2) were Infusion Related Reactions (IRRs).
- No subjects discontinued due to an AE related to ublituximab.
- A rapid infusion time, as low as one hour, of 450mg, was well tolerated, produced high levels of B cell depletion and
- is now being studied in the Phase 3 ULTIMATE trials in MS.

Post Reply
  • Similar Topics
    Replies
    Views
    Last post